D

D. Planchard

Université Paris-Saclay

Publishes on Lung Cancer Treatments and Mutations, HER2/EGFR in Cancer Research, Gastric Cancer Management and Outcomes. 13 papers and 70 citations.

13Publications

70Total Citations

Lung Cancer Treatments and Mutations HER2/EGFR in Cancer Research Gastric Cancer Management and Outcomes Colorectal Cancer Treatments and Studies Lung Cancer Research Studies

Is this you? Claim your profile.

Add your photo, update your bio, and get notified when your ranking changes.

Top publicationsby citations

975P Trastuzumab deruxtecan in patients (pts) with HER2-overexpressing (HER2-OE) metastatic non-small cell lung cancer (NSCLC): Results from the DESTINY-Lung01 trial

E.F. Smit, E. Felip, D. Uprety et al.|Annals of Oncology|2022

Cited by 16

Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis

Byoung Chul Cho, Y. Ohe, C. Zhou et al.|Annals of Oncology|2019

Cited by 11Open Access

PL03.13 Osimertinib With/Without Platinum-Based Chemotherapy as First-line Treatment in Patients with EGFRm Advanced NSCLC (FLAURA2)

Pasi A. Jänne, D. Planchard, Ying Cheng et al.|Journal of Thoracic Oncology|2023

Cited by 10Open Access

PL02.06 First-Line Osimertinib + Chemotherapy Versus Osimertinib Monotherapy in EGFRm Advanced NSCLC: FLAURA2 Final Overall Survival

D. Planchard, P.A. Jänne, K. Kobayashi et al.|Journal of Thoracic Oncology|2025

Cited by 10

OA16.05 Trastuzumab Deruxtecan Monotherapy in Pretreated HER2-overexpressing Nonsquamous Non-Small Cell Lung Cancer: DESTINY-Lung03 Part 1

D. Planchard, H.R. Kim, T. Suksombooncharoen et al.|Journal of Thoracic Oncology|2024

Cited by 9Open Access